SCHEDULE 13G/A: ARK Investment Management Divests Entire Stake in Ginkgo Bioworks Holdings, Inc.

ARK Investment Management LLC has filed an amended Schedule 13G indicating a complete divestment of its beneficial ownership in Ginkgo Bioworks Holdings, Inc., holding 0.0% of Class A Common Stock as of September 30, 2024.

Summary

• ARK Investment Management LLC, an investment adviser based in Delaware, has reported a 0.0% beneficial ownership in Ginkgo Bioworks Holdings, Inc.'s Class A Common Stock.
• This filing, Amendment No. 3 to Schedule 13G, indicates that ARK Investment Management LLC no longer holds any shares with sole or shared voting or dispositive power.
• The event requiring this filing occurred on September 30, 2024.
• The CUSIP number for the Class A Common Stock is 37611X209.
• The filing certifies that the securities were previously held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 2

Explanation: The complete divestment by a significant institutional investor like ARK Investment Management LLC is a strong negative signal, suggesting a lack of conviction in the company's future prospects from this particular fund.

Negatives

• ARK Investment Management LLC, a notable institutional investor, has completely divested its beneficial ownership in Ginkgo Bioworks Holdings, Inc., reducing its stake to 0.0%.

Future Outlook

NA

Industry Context

This filing reflects a portfolio adjustment by a significant institutional investor, ARK Investment Management LLC, which is known for its focus on disruptive innovation. While the filing itself does not provide reasons for the divestment, such a move by a prominent fund can be interpreted by the market as a change in investment thesis or a reallocation of capital away from Ginkgo Bioworks Holdings, Inc. within the broader biotechnology and synthetic biology sectors.

Stakeholder Impact

• Shareholders may react negatively to the news of a major institutional investor divesting its entire stake, potentially leading to downward pressure on the stock price.
• The divestment could influence other institutional investors' perceptions and investment decisions regarding Ginkgo Bioworks Holdings, Inc.

Key Dates

Recommendation

Keywords

Ginkgo Bioworks Holdings, ARK Investment Management, Schedule 13G, Beneficial Ownership, Divestment, Class A Common Stock, Institutional Investor, SEC Filing